Association of Prostate-Specific Antigen With Age, Digital Rectal Examination, and Lower Urinary Tract Symptoms in the Lebanese Population: A Cross-Sectional Study

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Sep 16

PMID 39280568

Authors

Yehya Tlaiss

Marc Jreij

Mohamad Tlais

Zahi F Yammine

Aziz M Najjar

Rania Naoufal

Hanadi Samaha

Marwan Najjar

Imad Ghantous

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer (PCa) is a leading cause of mortality in men worldwide. Prostate-specific antigen (PSA) testing is a standard method for PCa detection, yet its association with age, digital rectal examination (DRE) results, and lower urinary tract symptoms (LUTS) remains understudied, particularly in the Lebanese population.

Objective: This study aimed to investigate the association of PSA levels with age, DRE results, and LUTS severity among Lebanese men.

Methods: A total of 725 men aged 55-70 years were recruited from a men's health campaign at Saint George Hospital University Medical Center in Lebanon. PSA levels, DRE results, and International Prostate Symptom Score (IPSS) were assessed. Statistical analysis included Kruskal-Wallis tests and Spearman's rho correlation coefficient.

Results: Participants exhibited a significant correlation between age and PSA levels (r = 0.138, p < 0.01). PSA levels varied significantly across age groups (p = 0.029), with higher mean PSA levels observed in older age groups. IPSS status correlated positively with PSA levels (r = 0.23, p < 0.001), indicating higher PSA levels associated with increased LUTS severity. Abnormal DRE findings were significantly associated with elevated PSA levels (p < 0.00), suggesting their potential as an indicator of prostate abnormalities.

Conclusion: This study highlights the importance of age-specific reference ranges for PSA levels in the Lebanese population. Elevated PSA levels were associated with older age, increased LUTS severity, and abnormal DRE findings. These findings highlight the significance of integrating PSA testing with clinical assessments for PCa detection and risk stratification in Lebanon.

References

Senior K . Age-specific PSA screening better. Lancet Oncol. 2007; 8(5):378. DOI: 10.1016/s1470-2045(07)70126-2. View

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

Issa M, Zasada W, Ward K, Hall J, Petros J, Ritenour C . The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer Detect Prev. 2006; 30(3):269-75. DOI: 10.1016/j.cdp.2006.04.007. View

Hamilton W, Sharp D . Symptomatic diagnosis of prostate cancer in primary care: a structured review. Br J Gen Pract. 2004; 54(505):617-21. PMC: 1324845. View

Carter H, Albertsen P, Barry M, Etzioni R, Freedland S, Greene K . Early detection of prostate cancer: AUA Guideline. J Urol. 2013; 190(2):419-26. PMC: 4020420. DOI: 10.1016/j.juro.2013.04.119. View

Irwin D, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S . Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006; 50(6):1306-14. DOI: 10.1016/j.eururo.2006.09.019. View

Halpern J, Oromendia C, Shoag J, Mittal S, Cosiano M, Ballman K . Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. J Urol. 2017; 199(4):947-953. PMC: 6719551. DOI: 10.1016/j.juro.2017.10.021. View

Ostero I Jakupsstovu J, Brodersen J . Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?. BMJ. 2018; 361:k1202. DOI: 10.1136/bmj.k1202. View

Bakir M, Abo-daher D . Age-specific reference ranges for prostate-specific antigen among healthy Syrian men. Int J Biol Markers. 2012; 27(2):e152-9. DOI: 10.5301/JBM.2012.9304. View

10.

Turk H, Un S . Correlation between lower urinary tract symptoms and objective measures of uroflowmetry. Arch Ital Urol Androl. 2017; 89(2):130-133. DOI: 10.4081/aiua.2017.2.130. View

11.

Merriel S, Funston G, Hamilton W . Prostate Cancer in Primary Care. Adv Ther. 2018; 35(9):1285-1294. PMC: 6133140. DOI: 10.1007/s12325-018-0766-1. View

12.

Sheikh M, Sinan T, Kehinde E, Hussein A, Anim J, Al-Hunayan A . Relative contribution of digital rectal examination and transrectal ultrasonography in interpreting serum prostate-specific antigen values for screening prostate cancer in Arab men. Ann Saudi Med. 2007; 27(2):73-8. PMC: 6077036. DOI: 10.5144/0256-4947.2007.73. View

13.

Khezri A, Shirazi M, Taghi Ayatollahi S, Lotfi M, Askarian M, Ariafar A . Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol. 2009; 6(1):40-8. DOI: IJIv6i1A6. View

14.

Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L . Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270(7):860-4. View

15.

Nordstrom T, Engel J, Bergman M, Egevad L, Aly M, Eklund M . Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. Eur Urol Open Sci. 2021; 24:11-16. PMC: 8317798. DOI: 10.1016/j.euros.2020.12.004. View

16.

van Poppel H, Roobol M, Chapple C, Catto J, Ndow J, Sonksen J . Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021; 80(6):703-711. DOI: 10.1016/j.eururo.2021.07.024. View

17.

Gosselaar C, Roobol M, Roemeling S, Schroder F . The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol. 2008; 54(3):581-8. DOI: 10.1016/j.eururo.2008.03.104. View

18.

Patel D, Feng T, Simon R, Howard L, Vidal A, Moreira D . PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018; 21(2):238-244. DOI: 10.1038/s41391-018-0044-y. View

19.

Gyasi-Sarpong C, Acheampong E, Yeboah F, Aboah K, Laing E, Amoah G . Predictors of the international prostate symptoms scores for patients with lower urinary tract symptoms: A descriptive cross-sectional study. Urol Ann. 2018; 10(3):317-323. PMC: 6060591. DOI: 10.4103/UA.UA_4_17. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View